Ofev for PF-ILD Now Reimbursed in 7 regions of Canada
Ofev (nintedanib), a medicine approved to treat progressive fibrosing interstitial lung disease (PF-ILD), now is available for public reimbursement in Ontario, Quebec, New Brunswick, Newfoundland and Labrador, Alberta, and the Northwest Territories. The therapy also will be reimbursed through the Non-Insured Health Benefits (NIHB) program, which provides eligible First…